NCT05361005View on ClinicalTrials.gov

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

May 8, 2020

Study Completion Date

May 8, 2020

Conditions
Healthy
Interventions
DRUG

BDB-001 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

Trial Locations (1)

310022

Shu Lan (Hangzhou) Hospital, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Beijing Defengrei Biotechnology Co.,Ltd

UNKNOWN

lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT05361005 - Tolerability and Safety of BDB-001 Injection in Healthy Subjects | Biotech Hunter | Biotech Hunter